Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Position Boosted by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) by 8.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 116,254 shares of the medical equipment provider’s stock after purchasing an additional 8,706 shares during the period. Envestnet Asset Management Inc. owned approximately 0.06% of Zimmer Biomet worth $14,822,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in ZBH. Creative Capital Management Investments LLC bought a new position in shares of Zimmer Biomet during the 4th quarter valued at about $25,000. New England Capital Financial Advisors LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter worth about $27,000. Guardian Wealth Advisors LLC acquired a new position in shares of Zimmer Biomet in the third quarter worth about $28,000. General Partner Inc. acquired a new position in shares of Zimmer Biomet in the fourth quarter worth about $41,000. Finally, Old North State Trust LLC acquired a new position in shares of Zimmer Biomet in the third quarter worth about $54,000. Institutional investors own 87.21% of the company’s stock.

Insiders Place Their Bets

In other Zimmer Biomet news, VP Chad F. Phipps sold 23,045 shares of Zimmer Biomet stock in a transaction on Friday, March 17th. The shares were sold at an average price of $124.50, for a total transaction of $2,869,102.50. Following the sale, the vice president now owns 43,671 shares in the company, valued at $5,437,039.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.95% of the company’s stock.

Zimmer Biomet Trading Down 0.3 %

Shares of Zimmer Biomet stock opened at $137.44 on Tuesday. The company’s fifty day simple moving average is $130.19 and its 200-day simple moving average is $124.66. The company has a market cap of $28.67 billion, a price-to-earnings ratio of 64.22, a PEG ratio of 2.52 and a beta of 1.00. The company has a current ratio of 1.89, a quick ratio of 0.93 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 1 year low of $100.39 and a 1 year high of $149.25.

Zimmer Biomet (NYSE:ZBH – Get Rating) last announced its quarterly earnings data on Tuesday, May 2nd. The medical equipment provider reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.25. The business had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.70 billion. Zimmer Biomet had a net margin of 6.33% and a return on equity of 12.43%. Zimmer Biomet’s quarterly revenue was up 10.1% on a year-over-year basis. During the same quarter last year, the company posted $1.61 earnings per share. As a group, sell-side analysts expect that Zimmer Biomet Holdings, Inc. will post 7.45 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 28th. Shareholders of record on Wednesday, March 29th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Tuesday, March 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.70%. Zimmer Biomet’s dividend payout ratio is currently 44.86%.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Sanford C. Bernstein raised their target price on shares of Zimmer Biomet from $136.00 to $152.00 in a report on Wednesday, May 3rd. StockNews.com upgraded shares of Zimmer Biomet from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 3rd. Deutsche Bank Aktiengesellschaft raised their target price on shares of Zimmer Biomet from $121.00 to $147.00 in a report on Wednesday, May 3rd. Royal Bank of Canada raised their target price on shares of Zimmer Biomet from $141.00 to $156.00 in a report on Wednesday, May 3rd. Finally, UBS Group assumed coverage on shares of Zimmer Biomet in a research report on Tuesday, March 28th. They issued a “sell” rating and a $112.00 price target for the company. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $141.50.

About Zimmer Biomet

(Get Rating)

Zimmer Biomet Holdings, Inc engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products.